Hossein Borghaei, DO

Request an Appointment Online - Click Here New patients can request an appointment online or call

Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497

Video: Hossein Borghaei, DO

Hossein Borghaei, DO
Dr. Hossein Borghaei


Chief, Thoracic Oncology
Director, Lung Cancer Risk Assessment

Meet other members of the

Lung Cancer Patient Care Team

Learn more about Risk Assessment

Clinical Expertise:

Lung Cancer (Thoracic) Cancer Treatment


American Board of Internal Medicine;
National Board of Osteopathic Medical Examiners;
Medical Oncology

Medical Education

Philadelphia College of Osteopathic Medicine, 1996
MS in Microbiology and Immunology, Temple Medical School, Philadelphia, Pennsylvania


Graduate Hospital, Philadelphia, Pa.


Hematology-Oncology, Fox Chase Cancer Center, Chief Fellow

Research Interests

Molecular Therapeutics Program

Monoclonal Antibody; Targeted Therapy; Immunotherapy Cancer Vaccine

Research Interests

My laboratory is interested in immunotherapy for cancer, with particular emphasis on the clinical development and application of monoclonal antibodies. Recent work from my group includes a Phase I trial of naptumomab estafenatox, a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/E-120) linked to the antigen binding moiety of a monoclonal antibody recognizing the tumor-associated antigen 5T. In addition to developing new monoclonal antibodies, I am conducting clinical trials exploring the immunological responses that occur as a result of cetuximab therapy-associated antibody-dependent cellular cytotoxicity (ADCC)ADCC, with the goal of augmenting these immune responses to achieve improved efficacy of antibody therapy. In addition, I am involved in a number of clinical trials with various other monoclonal antibodies such as cetuximab. My latest lung cancer trial explores the relationship between EGFR and Aurora Kinase in lung cancer.